This is an expanded and updated report that includes:

  - 55 New Pages of Material
  - Charts, Timelines, Metrics and Financials Updated for 2011
  - 5-Year Projection Data Spanning 2011-2016
  - Expanded Competitive Environment Analysis
  - Detailed Characterization of the Market, Emphasizing Statistical Trending
  - Exploration of Recent Product Evolution and Projected Directions for Development
  - Overview of Therapeutic Progress and Insight into Future Applications
  - Detailed Evaluation of Profit Opportunities
  - New Section on End-User Interests, Needs, Technical Preferences (Scientist Panel)

Overview :  
Analysis of global grant activity, scientific publication rates, and patent applications reveal that research activity involving mesenchymal stem cells increased 58% year-over-year from 2008 to 2009, and 112% from 2009 to 2010. Of most interest is that this rate is accelerating in 2011, making mesenchymal stem cells the fastest growing area of stem cell research.

Mesenchymal stem cells (MSCs) are multipotent stem cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes, adipocytes, beta-pancreatic islets cells, and potentially, neuronal cells. MSCs are of intense therapeutic interest because they represent a population of cells with the potential to treat a wide range of acute and degenerative diseases. MSCs are advantageous over other stem cells types for several reasons. First, they avoid the ethical issues that surround embryonic stem cell research. Second, repeated studies have found that human MSCs are immuno-privileged, and therefore, represent an advantageous cell type for allogenic transplantation, reducing the risks of rejection and complications of transplantation. Recently, there have also been significant advances in the use of autologous MSCs to regenerate human tissues, including cartilage and meniscus, tendons, and bone fractures.

This market research report focuses on recent advances in MSC research applications, explores research priorities by market segment, highlights individual labs and end-users of MSC research products, explores the competitive environment for MSC research products, and provides 5-year growth and trend analysis. The report advantageously positions companies that wish to offer competitive stem cells products to this rapidly growing, well-funded research community.

II. Overview

    A. Definition
    B. Alternative Nomenclature
    C. Identification

          1. Characteristics
          2. Functional Attributes

    D. Benefits Relative to Other Stem Cell Types

III. Sources

    A. Fetal
    B. Adult

IV. Cell Types Derived from MSCs

V. Applications

    A. Basic Research Applications

          1. Directed Differentiation of Autologous MSCs to Intra-Mesenchymal Lineages

          2. Directed Differentiation of Autologous MSCs to Extra-Mesenchymal Lineages

    B. Supporting Hematopoietic Cells

    C. Gene Transfer Applications

    D. Cell-Based Therapy Applications

          1. Overview

          2. Major Applications

              a. Osteogenic-Focused Research Labs
              b. Myogenic and Myocardial-Focused Research Labs
              c. Adipogenic-Focused Research Labs

      3. Therapeutic Potential Beyond Mesenchymal Lineages

              a. Neuronal-Focused Research Labs
              b. Diabetic Treatment Applications

    E. Use of MSCs in 3-D Scaffolds for Tissue Engineering Applications

    F. Drug Delivery Applications: Engineered MSCs as carriers of anti-cancer drugs

    G. Drug Screening

    H. MSC-mediated Inhibition of Immune Effector Cells
 

VI. Application Priorities

    A. Overall

    B. By Segment

          1. Academic
          2. Biotech
          3. Pharma

VII. Companies Offering Human MSC Research Products

    A. Abcam
    B. BD Biosciences
    C. Celprogen
    D. Cyagen Biosciences (China only)
    E. Invitrogen
    F. LGC Standards/ATCC
    G. Lonza
    H. Millipore
    I. Miltenyi Biotec
    J. PAA - The Cell Culture Company
    K. PromoCell
    L. SA Biosciences
    M. ScienCell Research Laboratories
    N. Stem Cell Technologies
    O. Thermo Scientific
    P. R&D Systems

VIII. Companies Offering Rodent MSC Research Products

    A. Cell Applications
    B. Celprogen
    C. Cyagen Biosciences (China only)
    D. Genlantis
    E. Millipore
    F. Miltenyi Biotec
    G. ScienCell Research Laboratories
    H. Trevigen, Inc.
 

IX. Analysis of MSC Research Activity

    A. By Source

    B. By Clinical Application

    C. By Species

    D. By Country of Research

X. Market Trend Analysis

    A. Trailing 5 Years Data

          1. Scientific Publication Rate Analysis
          2. Grant Trend Rate Analysis
          3. Patent Analysis

    B. 5-Year Projection Data

          1. Scientific Publication Rate Analysis
          2. Grant Trend Rate Analysis
          3. Patent Analysis

XI. Mesenchymal Stem Cells as Tools for Drug Discovery

    A. Companies Developing Toxicology Screening Platforms for Stem Cells

    B. Potential Drug Screening Advantages of Rat MSCs

          1. Acquisition, Handling, and Differentiation Advantages

          2. Genetic Manipulation of MSCs

          3. Potential for Genetically Engineered MSC Reporter Lines

XII. Serum Free Supplements for Use in MSC Research

    A. Invitrogen, Inc.
    B. Celprogen
    C. Millipore, Inc.
    D. Stem Cell Technologies
    E. U.S. Patent 7109032: Serum-free medium for MSCs (Genoa, IT)

XIII. Potential Labs/Customers

    A. By Research Area

          1. General MSC Research Labs

          2. Osteogenic-Focused Research Labs

          3. Myogenic and Myocardial-Focused Research Labs

          4. Adipogenic-Focused Research Labs

          5. Neuronal-Focused Research Labs

          6. Immunology-Focused Research Labs

      B. By Industry Segment

          1. Commerical Labs

          2. NIH Labs

          3. Academic

XIV. End-User Preferences (Scientist Panel)

    A. Source Preference

    B. Species Preference

    C. Auxiliary Product Preferences

    D. Most-Commonly Used MSC Antibodies

XV. Research Product Opportunities & Suggestions

    A. RMSCs (Rat MSCs) Derived from Alternative Sources than Bone Marrow

    B. Novel RMSC Differentiation Kits

    C. Mesenchymal Stem Cell Expansion Media

    D. Antibodies to Mesenchymal Stem Cell Markers

    E. Mesenchymal Growth Factors

    F. Monoclonal Antibodies and Kits for Phenotyping RMSCs

    G. Chips for MicroArray Analysis of Gene Expression in RMSCs

    H. Optimized Bioreactors

    I. Clinical Grade MSCs

XVI. Conclusions